| First Author | Nazneen F | Year | 2023 |
| Journal | NPJ Vaccines | Volume | 8 |
| Issue | 1 | Pages | 50 |
| PubMed ID | 37005424 | Mgi Jnum | J:354759 |
| Mgi Id | MGI:7736510 | Doi | 10.1038/s41541-023-00650-w |
| Citation | Nazneen F, et al. (2023) An effective live-attenuated Zika vaccine candidate with a modified 5' untranslated region. NPJ Vaccines 8(1):50 |
| abstractText | Zika virus (ZIKV) is a mosquito-transmitted flavivirus that has caused devastating congenital Zika syndrome (CZS), including microcephaly, congenital malformation, and fetal demise in human newborns in recent epidemics. ZIKV infection can also cause Guillain-Barre syndrome (GBS) and meningoencephalitis in adults. Despite intensive research in recent years, there are no approved vaccines or antiviral therapeutics against CZS and adult Zika diseases. In this report, we developed a novel live-attenuated ZIKV strain (named Z7) by inserting 50 RNA nucleotides (nt) into the 5' untranslated region (UTR) of a pre-epidemic ZIKV Cambodian strain, FSS13025. We used this particular ZIKV strain as it is attenuated in neurovirulence, immune antagonism, and mosquito infectivity compared with the American epidemic isolates. Our data demonstrate that Z7 replicates efficiently and produces high titers without causing apparent cytopathic effects (CPE) in Vero cells or losing the insert sequence, even after ten passages. Significantly, Z7 induces robust humoral and cellular immune responses that completely prevent viremia after a challenge with a high dose of an American epidemic ZIKV strain PRVABC59 infection in type I interferon (IFN) receptor A deficient (Ifnar1(-/-)) mice. Moreover, adoptive transfer of plasma collected from Z7 immunized mice protects Ifnar1(-/-) mice from ZIKV (strain PRVABC59) infection. These results suggest that modifying the ZIKV 5' UTR is a novel strategy to develop live-attenuated vaccine candidates for ZIKV and potentially for other flaviviruses. |
